HUDDINGE, Sweden, Feb. 18, 2019 /PRNewswire/ -- Medivir AB
(Nasdaq Stockholm: MVIR) as previously announced, Erik Björk
will leave the role as Medivir's CFO. Lotta
Ferm will assume the role as interim CFO as of March 1st. Recruitment of a permanent CFO is
ongoing.
For further information, please contact:
Uli
Hacksell
CEO
Medivir AB
mobile: +46 (0)73 125 0615.
About Medivir
Medivir develops innovative drugs with a focus on cancer
where the unmet medical needs are high. The company is investing in
indication areas where available therapies are limited or missing
and there are great opportunities to offer significant improvements
to patients. Collaborations and partnerships are important parts of
Medivir's business model and the drug development as well as the
commercialization is conducted either by Medivir or in partnership.
Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's
Small Cap list. http://www.medivir.com/.
This information was brought to you by Cision
http://news.cision.com
http://news.cision.com/medivir/r/lotta-ferm-appointed-as-interim-cfo-at-medivir,c2743477
The following files are available for download:
|
https://mb.cision.com/Main/652/2743477/993045.pdf
|
Press release
(PDF)
|
View original
content:http://www.prnewswire.com/news-releases/lotta-ferm-appointed-as-interim-cfo-at-medivir-300797139.html
SOURCE Medivir
